Dr Fintan Walton, CEO and Founder of PharmaVentures, conducted the following interviews for PharmaTV during the AusBiotech 2015 national conference.

How the Biotech landscape is changing in Australia

Anna Lavelle, CEO of Ausbiotech, discusses the positive impact that recent political and legislative changes have had on Australia’s burgeoning biotech industry.

Can Opal Biosciences’ antimicrobial compound help the fight against antibiotic resistance?

Julie Phillips, Executive Director, BioDiem Ltd, discusses the work of their subsidiary company Opal Biosciences, who are developing a small molecule anti-microbial compound for drug-resistant infections.

The strategy behind IDT's move into specialty generics

During AusBiotech 2015 Dr Paul MacLeman, Managing Director, IDT Australia Ltd, was interviewed by Dr Fintan Walton. IDT have over 30 years of experience in contract manufacturing.

Interview with Dr Mark Ashton, Senior Director, Commercial Engagement, Health, UniQuest Pty Ltd

During AusBiotech 2015 Dr Mark Ashton, Senior Director, Commercial Engagement, Health, UniQuest Pty Ltd, was interviewed by Dr Fintan Walton.


How Benitec’s ddRNAi technology can overcome the challenges of siRNA-based methods

Georgina Kilfoil, Chief Clinical Officer of Benitec Biopharma Ltd, discusses Benitec’s unique gene-silencing technology.


Is Cortisol Inhibition the key to treating Alzheimer’s Disease?

Bill Ketelbey, CEO and Managing Director of Actinogen Ltd, discusses the development of their lead compound Xanamem™ , currently in clinical trials for the treatment of neurodegenerative diseases.


How Sienna Cancer Diagnostics are translating telomerase into a cancer biomarker.

Cliff Holloway, CEO,  Sienna Cancer Diagnostics Ltd, discusses the development and commercialisation of SCE-A7, the first telomerase detection product.


What’s behind Pharmaxis’ recent deal with Boehringer Ingleheim?

Gary Philips, CEO, Pharmaxis Ltd, reveals the reasons behind the company’s change in direction, leading up to one of the largest deals for a phase I asset in Australia.

Collagen-based cell regeneration: What makes Orthocell’s scaffold technology different from other collagen therapies?

Paul Anderson, Managing Director of Orthocell Ltd, reveals the unique technology behind their versatile therapy for tendon and soft-tissue injuries.


Ellume Pty Ltd, Australian Emerging Company of the Year

During AusBiotech 2015 Dr Sean Parsons, Managing Director, Ellume Pty Ltd was interviewed by Dr Fintan Walton.